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Editorial Comment
Utility of a Percutaneous Collagen
Hnn-nostasis Device: iro Plug or
Not to Plug?*
PHILIP B. KRAUSE, MD,
LLOYD W . KLEIN, MD, FACC
Chicago, Illinois
Does the utilization of a collagen vascular plug to seal
femoral artery puncture sites after coronary angiography and
intervention significantly alter patient outcome from that
obtained with conventional manual compression? In this
issue of the Journal, Sanborn and colleagues (1) present the
findings of a multicenter randomized trial that expand on
their previously published early experience with the collagen
device (2), It has now been sufficiently demonstrated that the
device has several advantages in achieving hemostasis,
including more convenience, less discomfort and diminished
time necessary for postcatheterization monitoring . These
benefits are noteworthy, but can the cost of this device be
defended on the basis of improved patient safety? If not,
how should the efficacy of this device be evaluated? In the
current environment of aggressive cost-reduction measures,
the results of clinical trials such as that of Sanborn et al . (1),
which suggest the potential for reducing costs through de-
creased length of hospital stay and personnel, do not substi-
tute for a thoughtfully conceived cost-effectiveness analysis
(3) . Consequently, although commercial advertising and
preliminary reports at national meetings havf . stimulated the
interest of the cardiology community, there is a need to
define precisely how the collagen device would improve
patient care and outcome, Before any technologic advance
can be advocated, the additional cost to the patient of
providing such care must be justified by conclusive evidence
of beneficial effects.
Current study. Sanborn et al . (1) address several impor-
tant issues, including the time required to achieve hemosta-
sisille time before ambulation is safely advised and the rate
of puncture site complications . Their most significant find-
ings are as follows . 1) The time needed to attain hemostasis
is decreased by about 14 min after diagnostic catheterization
(using 6F to SF) and by about 25 to 30 min after angioplasty
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(regardless of anticoagulationstatus) using the collagen plug
rather than conventional hand-held compression ; and 2) the
time interval between obtaining arterial access and ambula-
tion is decreased by about 6 h after catheterization and 9 to
16 h after angioplasty depending on when the device is
placed relative to completion of the intervention . This de-
creased time to ambulation must be considered a "soft" end
point because it was not part of a prospective design .
Additionally, most centers utilize a shorter supine restriction
period, usually 6 to 8 h, after diagnostic catheterization .
The study shows no difference with use of the plug in the
incidence of local groin complications, such as hematomas,
bleeding, pseudoaneurysms, need for surgical repair or
transfusion . However, the number of patients in the study is
too small to conclude that use of the device is safer or,
conversely, that its use may , actually lead to more compli-
cations than those associated with direct compression . If the
trend toward more hematomas after angioplasti with the
device in patients receiving heparin is confirmed in a larger
series, the investigators would have to reconsider their
conclusions concerning safety in this setting .
Conventional method . Traditionally, direct compression,
either manually or with a C-clamp device, after diagnostic
cardiac catheterization requires a time interval of 10 to
42 min until hemostasis is attained (4-6) . External femoral
artery compression, which has been used since cardiac
catheterization by the femoral approach was originally de-
scribed, is associated with a 0.23% to 5% rate of major
vascular complications (7-18). Earlier ambulation limes with
comparable complication rates have been reported (5,18)
with the use of 5F to 7F catheters, which are now standard
in many laboratories . Major nonthrombotic complications
include the formation of pseudoaneurysms and arterio-
venous fistulas requiring surgical repair and severe hemato-
mas requiring transfusion . Minor complications associated
with direct compression include smaller hematomas, local
discomfort and vasovagal reactions .
Vascular complication rates are increased in patients
requiring anticoagulation in association with percutaneous
interventional procedures (13) . Procedures using larger
sheath sizes and substantial anticoagulant regimens, such as
balloon valvuloplasty (10) and coronary stent implantation
(16,19), with respective complication rates of 7 .5% and 5%
to 8%, are of particular concern . Directional atherectomy
has been shown to require a longer hospital stay due to a
longer period of bed rest after sheath removal, with a
concomitant cost disadvantage, relative to balloon angio-
plasty (20) .
Collagen hemostatic devices . Collagen has been used to
attain hemostasis after surgical and dental procedures for
years. Before collagen could be applied in the catheteriza-
tion laboratory setting to obtain hemostasis after femoral
artery puncture, the development and refinement of technol-
ogy was required to ensure that the plug could be placed
reliably at the exterior of the vessel . Several commercial
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techniques have been tested, of which Vasoseal (Datascope
Corporation) is one . The procedure of deploying this device
is described in the study of Sanborn et al . (1) . Another
product is the Hemostatic Puncture Closure Device (HPCD .
Quinton Instrument Co
.), which utilizes a flat resorbable
polymer anchor placed inside the vessel lumen, to which a
collagen plug is then attached to the outer vessel wall by a
resorbable suture .
Complications with collagen devices . Although several
aspects of the hemostatic plug are attractive, many draw-
backs, complications or limitations are associated with its
use. These include problems also seen with manual compres-
sion, such as local hematoma, arteriovenous fistula or
pseudoaneurysm (21,22), which occur at rates of 0
.5% to
2%. In addition, the plug has attendant risks unique to its
use . Rarely, plug insertion or protrusion into the arterial
lumen has occurred with either local occlusion or distal
embolization requiring peripheral stent placement as a bridge
to surgery . There may be a higher risk of such complications in
patients undergoing procedures using larger sheath sizes, such
as intritaortic balloon pumping or atherectomy . Unless appro-
priate modifications of the device are developed, the applica-
bility of this technique would be limited in this large subset of
patients who would otherwise be likely to benefit from an
alternative method to achieve hemostasis .
Another problem specifically associated with the collagen
plug is that of repuncture at a recently plugged site
. The
textural change in the plug that occurs after deployment
renders the perivascular tissue indurated and nearly impen-
etrable during the initial days after use . In one study,
repuncture was attempted only after 2 to 14 weeks (4) . This
restriction in obtaining vascular access from the ipsilateral
vessel would necessitate changes in current management
strategies in patients with recurrent angina after angioplasty
and those who require intervention at a later time after
diagnostic catheterization .
Other common conditiops that may preclude safe deploy-
ment of this product include preexisting femoral hematoma,
multiple attempts at arterial access, extreme obesity of the
patient and severely scarred inguinal areas (4)
. In these
cases, direct compression may be preferred .
Cost-effectiveness study . An issue raised frequently by
hospital administrators and third-party payers is the cost-
effectiveness of a new device, in this case, the relative cost
of incorporating Vasoseal into routine postcatheteriz3ion
care. What benefit to outcome, as assessed medically or
economically, or both, is derived from the additional cost?
To resolve this issue, several questions need to be asked,
including : What are the overall costs of this product per
patient use? What savings are expected in terms of de-
creased length of stay and associated variable costs, such as
nursing labor and medical supplies? How large a reduction in
the rate of complications with use of this product would
warrant its use, and how many patients would be needed to
prove favorable cost and quality benefits?
In designing an appropriate trial, proof of both the clinical
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efficacy and cost-effectiveness (3) of the collagen plug com-
pared with those achieved with direct compression should be
primary goals
. If one assumes a 3% major vascular compli-
cation rate in the manual compression group in all patients
undergoing diagnostic catheterization, then it would require
1,338 patients in each of the two treatment subgroups to
prove a 50% reduction using the collagen plug (alpha = 0 .05,
1 tailed i test, 80% power) . To prove a 25% reduction using
these assumptions, 5,000 patients would he necessary in
each treatment group . A cost-effectiveness analysis is even
more sobering. Assuming the per use cost of the device to be
$120 versus an additional mean cost of --$8, /complication
(assuming a 2-day hospital stay plus surgical repair in
two-thirds of the patients with complications), a 50% reduc-
tion in complications is necessary to just break even (Table
I) . This rough analysis demonstrates that it would be much
wiser to test the device in higher risk patients with a larger
event rate (i .e., those receiving anticoagulant or postthrom-
bolytic therapy), but this would restrict its commercial
marketability as well as its potential impact on decreasing
costs through fostering outpatient catheteriz at ions .
Conclusions . The new plug devices will minimize patient
discomfort and impart reliable hemostasis utilizing the inher-
ent properties of collagen, which are active independent of
anticoagulation status . These are very attractive attributes
that deserve further study in the highest risk subgroups
.
However, the question remains whether improved outcome
should be anticipated in more routine cases .
Preliminary studies that demonstrate the potential of a
new device provide an important framework for definitive
trials . Sanborn and his co-authors are very careful about
drawing appropriate conclusions based on their experience
with the collagen plug in 246 patients . It is crucial, however,
that readers of the article critically distinguish between these
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initial observations and conclusive results
. Future investiga-
tions of this device should prospectively define the proposed
benefits and should be designed to explicitly test these
hypotheses. Finally, cardiologists should distinguish be-
tween conclusions drawn from scholarly presentations of
the clinical results using new "plug devices" from commer-
cial statements that are merely "devices to plug" new
products .
We thank Eugene Uretz, MS for statistical analysis, Ronald H . Whitaker,
MBA for reviewing the manuscript and Martha Westbrook for manuscript
preparation.
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